Form 4: VYNE Therapeutics CEO Receives Stock Grant
Insider Transaction (Form 4)
Rebecca Frey, Chief Executive Officer and a Director of VYNE Therapeutics Inc., received 465,857 shares of common stock on October 29, 2026.
Summary
- Grant/award: acquired 465,857 Stock Option (Right to Buy) on October 29, 2026; holds 465,857 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Rebecca Frey — Director, Officer (Chief Executive Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-29 | Grant/award | Stock Option (Right to Buy) | 465,857 | — | — | 465,857 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-29 | Grant/award (465,857 shares) |
Keywords
insider transaction, Form 4, YARW, Yarrow Bioscience, Inc., neutral, Rebecca Frey
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.